Skip to main
IBIO

iBio (IBIO) Stock Forecast & Price Target

iBio (IBIO) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

iBio is an innovative preclinical biotechnology company with a strong focus on utilizing AI technology to develop precision antibodies, reducing risks in downstream development. Their mission is to decrease drug development timelines and bring new treatments for hard-to-target diseases. Additionally, their valuation model and lead obesity candidates, IBIO-600 and IBIO-610, show potential for investors. However, investors should be aware of potential risks such as competition and potential patent infringement suits.

Bears say

iBio is heavily dependent on partnerships and collaborations, which may impact their bottom line and could lead to delays or setbacks in their drug development. Additionally, the company has a history of reporting significant losses and negative cash flow, which could be a cause for concern for investors. This, combined with a lack of revenue and high levels of debt, make iBio a risky investment. These factors, along with potential setbacks in drug development and competition in the market, contribute to our negative outlook on the company's stock.

iBio (IBIO) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iBio (IBIO) Forecast

Analysts have given iBio (IBIO) a Buy based on their latest research and market trends.

According to 4 analysts, iBio (IBIO) has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iBio (IBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.